Virios Therapeutics gets Nasdaq bid-price extension to Oct 30, 2023

Dogwood Therapeutics, Inc.

Received extension letter on May 2, 2023; new compliance period ends Oct 30, 2023.
Company meets all other Nasdaq listing requirements except $1.00 minimum bid price.
Intends to cure deficiency via reverse stock split if necessary.
If not compliant by Oct 30, 2023, Nasdaq could delist; company may appeal to Hearings Panel.
No assurance of regaining compliance or maintaining Nasdaq listing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.